OLMA Reports Encouraging Phase 1 Data for OP-3136, KAT6 Inhibitor Shows Anti-Tumor Activity, Manageable Safety Profile
Olema Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $12.71
-8.2% in 3d after detection
Post-detection moves
1h
—
1d
-2.7%
3d
-8.2%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS